US NEWS FEEDS
> NEW MEXICO
Two years' worth of work is starting to pay off for bioscience startup Agilvax. Medical professionals have reviewed and confirmed the Albuquerque-based company's preclinical trial results showing its treatments can "significantly reduce" tumor growth for a specific type of breast cancer.
Agilvax develops vaccines and targeted cancer immunotherapies. Creating treatments for triple-negative breast cancer is one of its main focuses at the moment. Depending on what stage it's detected, triple-negative…
Albuquerque Business News - Local Albuquerque News | Albuquerque Business First
READ MORE: ABQ bioscience startup touts medical breakthrough